Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Bavencio“
Suchtreffer
Begriffe & Kennungen
Bavencio · 4.8 · Among the 73 patients who were rechallenged with either avelumab (59%) or axitinib (85%) monotherapy or with b
Eintrag öffnenBavencio · 4.8 · Avelumab is associated with immune-mediated adverse reactions. Most of these, including severe reactions, reso
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.1% (2/2 082) of patients due to Type 1 diabetes mellitus. Type 1 diabetes melli
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.1% (2/2 082) of patients due to immune-mediated adrenal insufficiency. All 11 p
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (1/489) of patients due to Type 1 diabetes mellitus. All 5 patients with Typ
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (1/489) of patients due to immune-mediated thyroid disorders. Thyroid disord
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (4/2 082) of patients due to immune-mediated nephritis. All 7 patients with
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.2% (4/2 082) of patients due to immune-mediated thyroid disorders. Thyroid diso
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.4% (2/489) of patients due to immune-mediated colitis. All 13 patients with imm
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.4% (9/2 082) of patients due to immune-mediated pneumonitis. All 28 patients wi
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.5% (11/2 082) of patients due to immune-mediated colitis. All 31 patients with
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 0.6% (13/2 082) of patients due to immune-mediated hepatitis. All 21 patients wit
Eintrag öffnenBavencio · 4.8 · Avelumab was discontinued in 4.7% (23/489) of patients due to immune-mediated hepatitis. All 31 patients with
Eintrag öffnenBavencio · 4.8 · Data for immune-mediated adverse reactions for avelumab as a monotherapy are based on 2 082 patients including
Eintrag öffnenBavencio · 4.8 · Description of selected adverse reactions
Eintrag öffnenBavencio · 4.8 · Frequency Adverse reactions Blood and lymphatic system disorders Very common Anaemia Common Lymphopenia, throm
Eintrag öffnenBavencio · 4.8 · Frequency Adverse reactions Infections and infestations Uncommon Rash pustular* Blood and lymphatic system dis
Eintrag öffnenBavencio · 4.8 · Hepatotoxicity (in combination with axitinib) In patients treated with avelumab in combination with axitinib,
Eintrag öffnenBavencio · 4.8 · Immune checkpoint inhibitor class effects There have been cases of the following adverse reactions reported du
Eintrag öffnenBavencio · 4.8 · Immune-mediated adrenal insufficiency did not lead to discontinuation of avelumab in any patient. Eight (88.9%
Eintrag öffnen